Search
Results: 1
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
David RW Jayne, Annette N Bruchfeld, Lorraine Harper, Matthias Schaier, Michael C Venning, Patrick Hamilton, Volker Burst, Franziska Grundmann, Michel Jadoul, István Szombati, Vladimír Tesař, Mårten Segelmark, Antonia Potarca, Thomas J Schall, Pirow Bekker, CLEAR Study Group
May 13, 2019
Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168)...
ANCA ANCA-associated vasculitis avacopan complement complement 5a complement 5a receptor Adult Aged Aniline Compounds Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis cyclophosphamide Double-Blind Method Drug Therapy Combination Female Glucocorticoids Humans Immunosuppressive Agents Male Middle Aged Nipecotic Acids prednisone Receptor Anaphylatoxin C5a Rituximab Severity of Illness Index